Phathom Pharmaceuticals, Inc. PHAT Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $129.97M-56.3% | $297.26M-22.1% | $381.39M+145% | $155.39M-15.2% | ||
| $221.54M+197% | $74.61M+4,457% | $1.64M— | $0— | ||
| $92.52M+178% | $33.29M+294% | $8.46M— | $0— | ||
| $228.97M-36.4% | $360.13M-9.4% | $397.43M+148% | $160.51M-13.9% | ||
| $1.06M-27.9% | $1.48M-31.2% | $2.15M+77.8% | $1.21M+85.7% | ||
| $259.15M-31.5% | $378.32M-8.6% | $413.84M+151% | $164.81M-13.0% | ||
| $4.98M-52.6% | $10.51M-16.6% | $12.6M+26.0% | $10M+94.1% | ||
| $27.25M+37.8% | $19.78M+178% | $7.11M— | $0— | ||
| $0— | $0— | $0— | $0— | ||
| $132.04M+54.0% | $85.73M+121% | $38.78M+47.8% | $26.24M+38.7% | ||
| $209.09M+3.8% | $201.41M+46.1% | $137.84M+44.7% | $95.26M+6.2% | ||
| $697.32M+10.4% | $631.9M+29.9% | $486.6M+103% | $239.62M+104% | ||
| $6K0.0% | $6K+20.0% | $5K+66.7% | $3K0.0% | ||
| -$1.48B-17.5% | -$1.26B-36.0% | -$928.69M-27.7% | -$727.09M-37.4% | ||
| -$438.17M-72.8% | -$253.58M-249% | -$72.76M+2.7% | -$74.81M-204% | ||
| $259.15M-31.5% | $378.32M-8.6% | $413.84M+151% | $164.81M-13.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Phathom Pharmaceuticals, Inc.'s total assets?
- Phathom Pharmaceuticals, Inc. (PHAT) holds $305.1M in total assets, up 3.7% year over year.
- How much debt does Phathom Pharmaceuticals, Inc. have?
- Phathom Pharmaceuticals, Inc. carries $166.3M in total debt against -$337.0M of shareholders' equity, a debt-to-equity ratio of 5.64.
- How much cash does Phathom Pharmaceuticals, Inc. have?
- Phathom Pharmaceuticals, Inc. holds $180.9M in cash and equivalents.
- Can Phathom Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 2.21 — current assets exceed current liabilities.
- Where does Phathom Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
